¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"skin reactive factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • fibrin stabilizing factor
    ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ
  • fibroblast growth factor
    ¼¶À¯¸ð¼¼Æ÷¼ºÀåÀÎÀÚ
  • factor
    1. ÀÎÀÚ 2. ¿äÀÎ 3. °è¼ö
  • factor III
    Á¦3ÀÎÀÚ
  • factor IV
    Á¦4ÀÎÀÚ
  • factor IX
    Á¦9ÀÎÀÚ
  • factor IX complex
    Á¦9ÀÎÀÚº¹ÇÕü
  • factor V
    Á¦5ÀÎÀÚ
  • factor VI
    Á¦6ÀÎÀÚ
  • factor VII
    Á¦7ÀÎÀÚ
  • factor VIII
    Á¦8ÀÎÀÚ
  • factor X
    Á¦10ÀÎÀÚ
  • factor XI
    Á¦11ÀÎÀÚ
  • factor XII
    Á¦12ÀÎÀÚ
  • factor XIII
    Á¦13ÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • decay accelerating factor
    ºØ±«ÃËÁøÀÎÀÚ
  • dermonecrotic factor
    ÇǺα«»çÀÎÀÚ
  • diabetogenic factor
    ´ç´¢À¯¹ßÀÎÀÚ
  • dilution factor
    ¹±ÈûÀÎÀÚ, Èñ¼®ÀÎÀÚ
  • drug resistance factor
    ¾àÁ¦ÀúÇ×ÀÎÀÚ
  • elongation factor
    ´ÃÀÓÀÎÀÚ, ¿¬ÀåÀÎÀÚ
  • endothelium-derived contracting factor
    ³»ÇǼ¼Æ÷¼öÃàÀÎÀÚ
  • endothelium-derived relaxing factor
    ³»ÇǼ¼Æ÷ÀÌ¿ÏÀÎÀÚ
  • endurance factor
    Áö¼ÓÀÎÀÚ
  • eosinophil chemotactic factor
    È£»ê±¸È­ÇÐÁÖ¼ºÀÎÀÚ, È£»ê±¸È­Çнò¸²ÀÎÀÚ
  • epidermal growth factor
    Ç¥ÇǼºÀåÀÎÀÚ
  • exogenous factor
    ¿ÜÀοä¼Ò
  • extrinsic factor
    ¿ÜÀÎÀÎÀÚ, ¿ÜÀÎÀÚ
  • factor
    ÀÎÀÚ, ¿äÀÎ, °è¼ö
  • factor theory
    ¿äÀÎÀÌ·Ð
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
  • age factor
    ¿¬·ÉÀÎÀÚ.
  • air kerma calibration factor
    °ø±âÄ¿¸¶ÃøÁ¤°è¼ö, -´«±Ý¸ÂÃã°è¼ö
  • alveolar dilution factor
    ÆóÆ÷Èñ¼®ÀÎÀÚ(¡­ýüà·ì×í­).
  • amplification factor
    ÁõÆøÀÎÀÚ
  • anisotropy factor
    ºñµî¹æ¼º°è¼ö
  • antigen, colonization factor
    Áý¶ôÇü¼ºÀÎÀÚÇ׿ø, ¼¼Æ÷±ºÇü¼ºÀÎÀÚÇ׿ø
  • antihemophilic A factor =AHA
    Ç×Ç÷¿ìº´ AÀÎÀÚ(?ËöËö).
  • antihemophilic factor =AHF
    Ç×Ç÷¿ìº´ÀÎÀÚ(¡­ì×í­)
  • antihemophilic factor =AHF
    Ç×Ç÷¿ìº´ÀÎÀÚ(?ËöËö).
  • antihemophllic factor
    Ç×Ç÷¿ìº´ÀÎÀÚ
  • antiinsulin factor
    Ç×Àν¶¸°ÀÎÀÚ.
  • antineuritic factor
    Ç׽Ű濰ÀÎÀÚ(ù÷ãêÌèæúì×í­).
  • antinuclear factor =ANF
    Ç×ÇÙÀÎÀÚ.
  • antipellagra factor
    Çׯç¶ó±×¶óÀÎÀÚ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • skin dose
    ÇǺμ±·®
  • skin erythema dose
    ÇǺιßÀû¼±·®
  • skin flap
    ÇÇÆÇ(ù«÷û), ÇÇºÎÆí(ù«Ý±ø¸).
  • skin flare
    ÇǺιßÀû(¡­Û¡îå)
  • skin flare
    ÇǺιßÀû(¡­Û¡îå)
  • skin fold
    ÇǺÎÁÖ¸§
  • skin folds
    ÇǺÎÁÖ¸§.
  • skin folds
    ÇǺÎÁÖ¸§(ù«Ý±¡­)
  • skin friction
    ÇǺθ¶Âû(¡­Ø¤óÍ)
  • skin graft
    ÇǺÎÀ̽Ä
  • skin graft
    ÇǺÎÀ̽Ä(Æí)(¡­ì¹ãÕø¸).
  • skin graft thickness
    ÀüÃþÇǺÎÀÌ½ÄÆí(îïöµù«Ý±ì¹ãÖø¸).
  • skin grafting
    ÇǺÎÀ̽Ä(¼ú)(¡­ì¹ãÕâú).
  • skin infections
    ÇǺΰ¨¿°(Áõ)(¡­Êïæøñø).
  • skin infections
    ÇǺΰ¨¿°(Áõ)(¡­Êïæøñø)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • lard factor
    µ·Áö(ÔÊò·) ÀÎÀÚ(ì×í­)
  • leukocyte inhibitory factor
    ¹éÇ÷±¸ÀúÇØÀÎÀÚ(ÛÜúìϹîÁúªì×í­)
  • Lewis factor
    ·çÀ̽ºÀÎÀÚ(ì×í­)
  • lipoprotein tissue factor
    ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ) Á¶Á÷ÀÎÀÚ(ðÚòÄì×í­)
  • liver filtrate factor
    °£ ¿©°ú ÀÎÀÚ(ÊÜÕëΦì×í­)
  • LLD factor
    LLD ÀÎÀÚ(ì×í­)
  • L-L factor
    "L-L ÀÎÀÚ(ì×í­), (å²) Laki-Lorand ÀÎÀÚ(ì×í­)"
  • lymph node permeability factor
    ¸²ÇÁÀý(ï½)Åõ°úÀÎÀÚ(÷âΦì×í­)
  • lymphocyte-derived chemotactic factor
    ¸²ÇÁ±¸-À¯µµ(ë¯Óô) È­ÇÐÁÖ¼ºÀÎÀÚ(ûùùÊñËà÷ì×í­)
  • macrophage activation factor
    ´ë½Ä¼¼Æ÷Ȱ¼ºÀÎÀÚ(ÓÞãÝá¬øàüÀàõì×í­)
  • macrophage inhibition factor
    ´ë½Ä¼¼Æ÷ÀúÇØÀÎÀÚ(ÓÞãÝá¬øàîÁúªì×í­)
  • maize factor
    ¿Á¼ö¼ö ÀÎÀÚ(ì×í­)
  • maturation factor
    ¼º¼÷ÀÎÀÚ(à÷âÙì×í­)
  • migration enhancement factor
    À̵¿Ç×Áø ÀÎÀÚ(ì¹ÔÑùñòäì×í­)
  • migration inhibition factor
    À̵¿ÀúÇØ ÀÎÀÚ(ì¹ÔÑîÁúªì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
CRP C-Reactive Protein; - 0.06 mg/dL
ReA Reactive Arthritis
ARC accelerating rate calorimetry; acquired immunodeficiency syndrome-related complex; active renin conc...
BRA bilateral renal agenesis; bone-resorbing activity; brain-reactive antibody
BRM biological response modifier; biuret reactive material
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
RSL reactive site loop
SARA sexually acquired reactive arthritis
SICRI substance immunologically cross reactive with insulin
CSS Cultured skin substitutes
FST Finger Skin Temperature
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • complementary factor
    º¸Ãæ ÀÎÀÚ
  • complicating factor
    º¹ÇÕ ¿äÀÎ
  • constitutional factor
    ±¸¼º ¿ä¼Ò, üÁú ¿äÀÎ
  • contributing factor
    ±â¿© ¿äÀÎ
    ÁúȯÀ̳ª Àå¾Ö¸¦ À¯¹ßÇϰųª ¾ÇÈ­Çϴµ¥ ±â¿©ÇÏ´Â »óųª Çൿ.
  • conversion factor
    º¯È¯ °è¼ö
  • cooperative factor
    Çùµ¿ ÀÎÀÚ
  • coronary risk factor
    °ü»ó µ¿¸Æ Áúȯ À§Çè ¿äÀÎ
  • cothromboplastin factor VII
    ÄÚÆ®·Ò º¸ÇÃ¶ó½ºÆ¾
  • coupling factor
    ¹è¿ì ÀÎÀÚ
  • covering factor
    ÇǺ¹ ÀÎÀÚ
  • cultural and ethnic factor
    ¹®È­ ¹ÎÁ·Àû ¿äÀÎ
  • cytotoxic factor
    ¼¼Æ÷ µ¶¼º ÀÎÀÚ
  • D and C ÀÚ±ÃÀÇ °æºÎ È®Àå°ú ³»¸· ¼ÒÆÄ.

    D factor

    D-ÀÎÀÚ
  • Decay accelerating factor
    ºØ±« °¡¼Ó ¿ä¼Ò
  • diabetogenic factor
    ´ç´¢ À¯¹ß ÀÎÀÚ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
deciduous skin 1. Separation or loosening of the horny layer of the epidermis.
2. Specifically, a disease characterised by a shedding of the epidermis recurring at more or less regular intervals.
Synonym: deciduous skin.
Origin: kerato-+ G. Lysis, loosening
(05 Mar 2000)
syndrome, scalded skin See Scalded skin syndrome.
(12 Dec 1998)
diamond skin The appearance of the affected site in erysipeloid.
(05 Mar 2000)
diamond skin disease A form of swine erysipelas, caused by the bacterium Erysipelothrix rhusiopathiae, in which rhomboidal erythematous areas appear on the skin.
(05 Mar 2000)
infantile acute haemorrhagic oedema of the skin A generally benign form of cutaneous vasculitis, characterised by ecchymotic purpura, often in a cockade pattern, and inflammatory oedema in infants.
(05 Mar 2000)
test, skin, for allergy A test done on the skin to identify the allergy substance (allergen) triggering the allergic reaction. A small amount of the suspected allergy substance is placed on the skin. The skin is then gently scratched through the small drop with a special sterile needle. If the skin reddens and, more importantly, swells, then allergy to that substance is probable.
(12 Dec 1998)
elastic skin
toad skin A follicular hyperkeratotic eruption thought to be due to deficiency of vitamin A.
Synonym: toad skin.
Origin: G. Phrynos, toad, + derma, skin
(05 Mar 2000)
tuberculin skin test See: Mantoux test, Heaf test, tuberculin tine test
(18 Nov 1997)
tubular glands of the skin The blind extremity of which is coiled in the form of a ball or glomerulus; collective term for small eccrine and large apocrine sweat glands.
(05 Mar 2000)
yellow skin The occurrence of patches of yellow colour in the skin, resembling xanthoma, but without the nodules or plates.
Synonym: cholesteroderma, xanthochroia, xanthoderma, xanthopathy, yellow disease, yellow skin.
Origin: xantho-+ G. Chroma, colour
(05 Mar 2000)
farmer's skin Dry, wrinkled skin with presence of dry premalignant keratoses; observed most commonly in fair-skinned, blue-eyed persons who are exposed by occupation or sport to sunshine for prolonged periods and over many years.
Synonym: golfer's skin, sailor's skin.
(05 Mar 2000)
layers of skin See: epidermis, dermis.
(05 Mar 2000)
lepromin skin test <investigation> A test for leprosy where an extract of infected tissue (antigen) is injected under the skin to determine if you have a current or recent leprosy infection.
Normally, little or no skin reaction should result from the injection. A positive skin reaction indicates a leprosy infection.
(27 Sep 1997)
loose skin A group of connective tissue diseases in which skin hangs in loose pendulous folds. It is believed to be associated with decreased elastic tissue formation as well as an abnormality in elastin formation. Cutis laxa is usually a genetic disease, but acquired cases have been reported.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á